Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.34 |
| ▸ | CTSS | P25774 | 7/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | LYN | P07948 | 1/20 | 0.31 |
| ▸ | HCK | P08631 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | FRK | P42685 | 1/20 | 0.31 |
| ▸ | BLK | P51451 | 1/20 | 0.31 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3319601 | 0.96 | CTSS (0.34) | GPR119CTSSNSD2 | |
| SCHEMBL3318584 | 0.91 | CTSS (0.38) | GPR119CTSSNSD2JAK3BTK | |
| SCHEMBL3319971 | 0.91 | CTSS (0.40) | GPR119CTSSNSD2JAK3BTK | |
| SCHEMBL8130225 | 0.88 | SRC (0.35) | GPR119LCKFYNLYNHCK | |
| Trifluoroacetic Acid SCHEMBL3320169 | 0.86 | CTSS (0.37) | CTSSCTSLCTSK | |
| SCHEMBL3315815 | 0.83 | CDK1 (0.39) | CTSSCTSL | |
| SCHEMBL3320009 | 0.82 | CDK1 (0.41) | CTSSCTSLCTSK | |
| SCHEMBL8135722 | 0.82 | CTSS (0.41) | GPR119CTSSCTSKPIK3CD | |
| SCHEMBL3317204 | 0.82 | CTSL (0.34) | CTSSCTSLCTSK | |
| SCHEMBL3319215 | 0.81 | CTSL (0.46) | GPR119CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | claimed |
| EP-2118106-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | claimed |
| WO-2008107368-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | claimed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| EP-2118106-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008107368-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | CPN1, SERPINB1, PNP | GPR119 3370/4885CTSS 37/4885NSD2 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.